Skip to search formSkip to main contentSkip to account menu

saridegib

An orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, Saridegib… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

IPI-926

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis
Introduction Drugs that target activating mutations of Janus Kinase 2 (JAK2) have been the backbone of myelofibrosis (MF… 
Review
2014
Review
2014
Genetic alterations in chondrosarcomas – keys to targeted therapies?
Chondrosarcomas are malignant tumors of chondrocytes and represent the second most common type of primary bone tumors. Within the… 
2013
2013
Targeted therapies for medulloblastoma: understanding the mechanisms of drug resistance and exploring new peptide-based therapeutics
Medulloblastoma, the most common malignant pediatric brain tumor, is currently treated with nonspecific cytotoxic therapies… 
2012
2012
Hedgehog hopes lifted by approval... and stung by failure
2012
2012
401 Impact of Saridegib (IPI-926) On Smoothened Ciliary Localization and Hedgehog Pathway Activity
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)